Engineered ligand-based VEGFR antagonists with increased receptor binding affinity more effectively inhibit angiogenesis-Reference-Cited by-同舟云学术

Engineered ligand-based VEGFR antagonists with increased receptor binding affinity more effectively inhibit angiogenesis

Author:

Kapur Shiven¹,Silverman Adam P.¹,Ye Anne Z.¹,Papo Niv¹,Jindal Darren¹,Blumenkranz Mark S.²,Cochran Jennifer R.¹³⁴

Affiliation:

1. Dept. of Bioengineering; Stanford University; Stanford CA 94303

2. Dept. of Ophthalmology; Byers Eye Institute, Stanford University; Stanford CA 94303

3. Dept. of Chemical Engineering; Stanford University; Stanford CA 94303

4. Stanford Cancer Institute; Stanford University; Stanford CA 94303

Funder

American Cancer Society Research Scholars

National Institutes of Health

European Molecular Biology Organization

Stanford Bio-X and NSF Graduate Research Fellowships (to A.Z.Y.)

Stanford Bioengineering REU program (to D.J.)

Publisher

Wiley

Subject

Pharmaceutical Science,Biomedical Engineering,Biotechnology

Reference52 articles.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献